December 8, 2025Blood

Nfkb signaling in idecabtagene vicleucel infusion product drives response in relapsed/refractory multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

JNJerald NobleMoffitt Cancer Center GAGabriel De AvilaMoffitt Cancer Center OPOmar Castañeda PuglianiniMoffitt Cancer Center

Discussion

Member takes

Implication

Single-cell RNA sequencing reveals that Nfkb signaling correlates with CAR-T efficacy in relapsed/refractory multiple myeloma, suggesting the tumor microenvironment plays a vital role.

Key Points

Cytotoxicity of CAR-T therapy in multiple myeloma is linked to Nfkb signaling, as shown by single-cell RNA sequencing analysis.
Gene expression analysis identified key factors in the tumor microenvironment associated with CAR-T responses.
Chimeric antigen receptor T-cell infusion showed enhanced efficacy linked to enriched gene set profiles and signaling pathways.
The study highlights the importance of pre-existing tumor microenvironment conditions on CAR-T product performance.

Cite This Study

Noble et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e50d https://doi.org/10.1182/blood-2025-504

View Full Paper

Ask AI

Bookmark

Implication

Single-cell RNA sequencing reveals that Nfkb signaling correlates with CAR-T efficacy in relapsed/refractory multiple myeloma, suggesting the tumor microenvironment plays a vital role.

Nfkb signaling in idecabtagene vicleucel infusion product drives response in relapsed/refractory multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Nfkb signaling in idecabtagene vicleucel infusion product drives response in relapsed/refractory multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider